Ebola virus disease: Recent advances in diagnostics and therapeutics

被引:0
作者
Supriya Jagga [1 ]
Ashish Ranjan Sharma [1 ]
Chiranjib Chakraborty [1 ,2 ]
Sang-Soo Lee [1 ]
机构
[1] Institute for Skeletal Aging & Orthopedic Surgery, Chuncheon Sacred Heart Hospital, Hallym University
[2] Department of Biotechnology, School of Life Science and Biotechnology, Adamas University
基金
新加坡国家研究基金会;
关键词
Ebola virus; Vaccines; Therapeutics; Ebola outbreaks; Diagnostics; Epidemiology; Haemorrhagic fever;
D O I
暂无
中图分类号
R512.8 [病毒性出血热];
学科分类号
100401 ;
摘要
Ebola virus disease(EVD)is associated with haemorrhagic fever in humans and nonhuman primates,with a high rate of fatality(up to 90%).Some outbreaks in human history have proven the lethality of EVD.The recent epidemic of 2014 and 2015 in West Africa was the deadliest of all time(11 284 deaths).To understand the transmission dynamics,we have reviewed the epidemiology of EVD to date.The absence of any licensed vaccines or approved drugs against Ebola virus(EBOV)further highlights the severity and crisis level of EVD.Some organizations(public and private)are making considerable efforts to develop novel therapeutic approaches or vaccines to contain the outbreak of EBOV shortly.Here,we summarized the various potential drugs and vaccines(undergoing multiple phases of clinical trials)that have arisen as an alternative against EBOV,and we highlighted the numerous issues and limitations hindering this process.Alternatively,an increasing focus on strengthening the medical and civic health structure could provide speedy benefits in containing the spread of EVD,as well as offer a resilient foundation for the deployment of novel drugs and vaccines to the affected countries,once such drugs and vaccines become available.
引用
收藏
页码:385 / 395
页数:11
相关论文
共 25 条
[1]   Ebola virus disease: past, present and future [J].
Harish Rajak ;
Deepak Kumar Jain ;
Avineesh Singh ;
Ajay Kumar Sharma ;
Anshuman Dixit .
Asian Pacific Journal of Tropical Biomedicine, 2015, (05) :337-343
[2]  
Prevention of Ebola virus disease through vaccination: where we are in 2018[J] . Yves Lévy,Clifford Lane,Peter Piot,Abdul Habib Beavogui,Mark Kieh,Bailah Leigh,Seydou Doumbia,Eric D’Ortenzio,Claire Lévy-Marchal,Jerome Pierson,Deborah Watson-Jones,Vinh-Kim Nguyen,Heidi Larson,Julia Lysander,Christine Lacabaratz,Rodolphe Thiebaut,Augustin Augier,David Ishola,Stephen Kennedy,Geneviève Chêne,Brian Greenwood,James Neaton,Yazdan Yazdanpanah.The Lancet . 2018 (1014)
[3]   Open-label phase I clinical trial of Ad5-EBOV in Africans in China [J].
Wu, Lihua ;
Zhang, Zhe ;
Gao, Hainv ;
Li, Yuhua ;
Hou, Lihua ;
Yao, Hangping ;
Wu, Shipo ;
Liu, Jian ;
Wang, Ling ;
Zhai, You ;
Ou, Huilin ;
Lin, Meihua ;
Wu, Xiaoxin ;
Liu, Jingjing ;
Lang, Guanjing ;
Xin, Qian ;
Wu, Guolan ;
Luo, Li ;
Liu, Pei ;
Shentu, Jianzhong ;
Wu, Nanping ;
Sheng, Jifang ;
Qiu, Yunqing ;
Chen, Wei ;
Li, Lanjuan .
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2017, 13 (09) :2078-2085
[4]   Discovering Drugs for the Treatment of Ebola Virus [J].
Sandra L. Bixler ;
Allen J. Duplantier ;
Sina Bavari .
Current Treatment Options in Infectious Diseases, 2017, 9 (3) :299-317
[5]  
Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: An open phase I/II trial in healthy adults in Russia[J] . I. V. Dolzhikova,O. V. Zubkova,A. I. Tukhvatulin,A. S. Dzharullaeva,N. M. Tukhvatulina,D. V. Shcheblyakov,M. M. Shmarov,E. A. Tokarskaya,Y. V. Simakova,D. A. Egorova,D. N. Scherbinin,I. L. Tutykhina,A. A. Lysenko,A. V. Kostarnoy,P. G. Gancheva,T. A. Ozharovskaya,B. V. Belugin,L. V. Kolobukhina,V. B. Pantyukhov,S. I. Syromyatnikova,I. V. Shatokh
[6]  
Recent advances in the development of vaccines for Ebola virus disease[J] . Elijah Ige Ohimain.Virus Research . 2016
[7]  
Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea[J] . Daouda Sissoko,Cedric Laouenan,Elin Folkesson,Abdoul-Bing M’Lebing,Abdoul-Habib Beavogui,Sylvain Baize,Alseny-Modet Camara,Piet Maes,Susan Shepherd,Christine Danel,Sara Carazo,Mamoudou N. Conde,Jean-Luc Gala,Géraldine Colin,Hélène Savini,Joseph Akoi Bore,Frederic Le Marcis,Fara Raymond Koundouno,Frédéric Petitjean,Marie-Claire Lamah,Sandra
[8]  
Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice[J] . Karin L?vgren Bengtsson,Haifeng Song,Linda Stertman,Ye Liu,David C. Flyer,Michael J. Massare,Ren-Huan Xu,Bin Zhou,Hanxin Lu,Steve A. Kwilas,Timothy J. Hahn,Eloi Kpamegan,Jay Hooper,Ricardo Carrion,Gregory Glenn,Gale Smith.Vaccine . 2016
[9]  
Clinical development of Ebola vaccines[J] . Saranya Sridhar.Therapeutic Advances in Vaccines . 2015 (5-6)
[10]   Ebola viral disease and pregnancy [J].
Black, Benjamin O. ;
Caluwaerts, Severine ;
Achar, Jay .
OBSTETRIC MEDICINE, 2015, 8 (03) :108-113